Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 2/3 3Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 7Stomach Neoplasms 3Adenocarcinoma Of Esophagus 3Uveal Melanoma 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hepatitis B 1Gliosarcoma 1GATA2 Deficiency 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Malignancies 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 3Ramucirumab 2Radiotherapy 2Paclitaxel 2Cisplatin 2Capecitabine 2tucatinib 1Trastuzumab 1Taxes 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Cetuximab 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma Of Esophagus × Nivolumab × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07221149 2026-05-14

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07392892 2026-04-13

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Pfizer

Phase 2/3 Recruiting
840 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡